EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis

Carmel Awadallah, Anas Zayad iD, Shebli Atrash iD, Anita Mazloom iD, Omar Alkharabsheh iD, Prerna Mewawalla iD, Mansi R Shah, Forat Lutfi iD, Zahra Mahmoudjafari iD, Muhammad Umair Mushtaq, Jeries Kort iD, Alma Habib und 1 weitere

Current Oncology · 27.04.2026 · 33 (5) · 249

DOI: 10.3390/curroncol33050249 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Current Oncology, online erschienen am 27.04.2026. Verfasst von Carmel Awadallah und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, St John Episcopal Hospital, Far Rockaway, NY 11691, USA. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-risk cytogenetic multiple myeloma (HRMM) confers inferior outcomes despite significant therapeutic advances. Real-world data characterizing contemporary treatment patterns across lines of therapy in this population are limited.

Methods

We conducted a multicenter retrospective study of 205 patients with HRMM diagnosed between January 2009 and January 2024. High-risk cytogenetics were defined according to the International Myeloma Working Group (IMWG) and Revised International Staging System (R-ISS) criteria as the presence of del(17p), t(4;14), t(14;16), t(14;20), and/or gain/amplification of 1q21. Treatment regimens were categorized by the number of agents (doublet, triplet, quadruplet), mechanism of action (proteasome inhibitor [PI]-based, immunomodulatory drug [IMiD]-based, and anti-CD38 monoclonal antibody-based), and specific regimen composition. Treatment patterns were analyzed across three treatment eras and stratified by age (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansRetrospective StudiesMiddle AgedMaleFemaleAged

Stichwörter der Autor:innen

autologous stem cell transplantationhigh-risk cytogeneticsimmunomodulatory druginduction therapymultiple myelomaproteasome inhibitorreal-world evidencetreatment patterns

Autor:innen und Institutionen

  • Division of Internal Medicine, St John Episcopal Hospital, Far Rockaway, NY 11691, USA.
  • Department of Internal Medicine, Hamad Medical Corporation, Doha 3050, Qatar.
  • Levine Cancer Center, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28204, USA.
  • Division of Hematology and Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
  • Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH 45219, USA.
  • Division of Hematology and Bone Marrow Transplant, Alleghany Medical Center, Pittsburg, PA 15212, USA.

ORCID-Profile: Anas Zayad, Shebli Atrash, Anita Mazloom, Omar Alkharabsheh, Prerna Mewawalla, Forat Lutfi, Zahra Mahmoudjafari, Jeries Kort, Al-Ola Abdallah

Zitieren

APA

Awadallah, C., Zayad, A., Atrash, S., Mazloom, A., Alkharabsheh, O., Mewawalla, P., Shah, M. R., Lutfi, F., Mahmoudjafari, Z., Umair Mushtaq, M., Kort, J., Habib, A., & Abdallah, A. O. (2026). High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis. Current Oncology, 33(5), 249. https://doi.org/10.3390/curroncol33050249

Vancouver

Awadallah C, Zayad A, Atrash S, Mazloom A, Alkharabsheh O, Mewawalla P, et al. High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis. Current Oncology. 2026;33(5):249. doi:10.3390/curroncol33050249

BibTeX
@article{Awadallah2026,
  author = {Awadallah, Carmel and Zayad, Anas and Atrash, Shebli and Mazloom, Anita and Alkharabsheh, Omar and Mewawalla, Prerna and Shah, Mansi R and Lutfi, Forat and Mahmoudjafari, Zahra and Umair Mushtaq, Muhammad and Kort, Jeries and Habib, Alma and Abdallah, Al-Ola},
  title = {High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {5},
  pages = {249},
  doi = {10.3390/curroncol33050249}
}
Kostenlos starten →